Document:

<PAGE>
                                                                    Exhibit 10.3

                                    FORM OF

                             STRATAGENE CORPORATION

                          EMPLOYEE STOCK PURCHASE PLAN
<PAGE>
                                                                               .
                                                                               .
                                                                               .
                                    FORM OF

                             STRATAGENE CORPORATION

                          EMPLOYEE STOCK PURCHASE PLAN

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            PAGE
<S>                                                                         <C>
1.   Definitions..........................................................     1

2.   Stock Subject to the Plan............................................     3

3.   Grant of Options.....................................................     3

4.   Exercise of Options; Option Price....................................     4

5.   Withdrawal from the Plan.............................................     5

6.   Termination of Employment............................................     6

7.   Restriction upon Assignment..........................................     6

8.   No Rights of Stockholders until Shares Issued........................     6

9.   Changes in the Stock and Corporate Events; Adjustment of Options.....     6

10.  Use of Funds; No Interest Paid.......................................     8

11.  Amendment, Suspension or Termination of the Plan.....................     8

12.  Administration by Committee; Rules and Regulations...................     8

13.  Designation of Subsidiary Corporations...............................     9

14.  No Rights as an Employee.............................................     9

15.  Term; Approval by Stockholders.......................................     9

16.  Effect upon Other Plans..............................................     9

17.  Conditions to Issuance of Stock Certificates.........................    10

18.  Notification of Disposition..........................................    10

19.  Notices..............................................................    10

20.  Additional Restrictions of Rule 16b-3................................    10

21.  Equal Rights and Privileges..........................................    11

22.  Headings.............................................................    11
</TABLE>
<PAGE>
                                    FORM OF

                           THE STRATAGENE CORPORATION

                          EMPLOYEE STOCK PURCHASE PLAN

            Stratagene Corporation, a Delaware corporation (the "Company"),
hereby adopts the Stratagene Corporation Employee Stock Purchase Plan (the
"Plan"), effective as of _______________, 2004.

            The purposes of the Plan are as follows:

                  (1)   To assist eligible employees of the Company and its
      Designated Subsidiaries (as defined below) in acquiring stock ownership in
      the Company pursuant to a plan which is intended to qualify as an
      "employee stock purchase plan," within the meaning of Section 423(b) of
      the Code (as defined below).

                  (2)   To help such employees provide for their future security
      and to encourage them to remain in the employment of the Company and its
      Subsidiary Corporations.

      1.    DEFINITIONS. Whenever any of the following terms is used in the Plan
with the first letter or letters capitalized, it shall have the following
meaning unless context clearly indicates to the contrary (such definitions to be
equally applicable to both the singular and the plural forms of the terms
defined):

            (a)   "ACCOUNT" shall mean the account established for a Participant
under the Plan with respect to an Offering Period.

            (b)   "AUTHORIZATION" shall mean a Participant's payroll deduction
authorization with respect to an Offering Period provided by such Participant in
accordance with Section 3(b).

            (c)   "BOARD" means the Board of Directors of the Company.

            (d)   "CODE" means the Internal Revenue Code of 1986, as amended.

            (e)   "COMMITTEE" means the committee of the Board appointed to
administer the Plan pursuant to Section 12.

            (f)   "COMPANY" means Stratagene Corporation, a Delaware
corporation.

            (g)   "COMPENSATION" of an Employee shall mean all compensation
received by such Employee from the Company or any Designated Subsidiary on each
Payday as compensation for services to the Company or any Designated Subsidiary,
including all salary, wages (including amounts elected to be deferred by the
Employee, but which would otherwise have been paid, under any cash or deferred
arrangement established by the Company or a Designated Subsidiary), overtime
pay, sales commissions, bonuses, and other remuneration paid directly to the
Employee; but excluding the cost of employee benefits paid by the Company or a
Designated Subsidiary, education or tuition reimbursements, imputed income
arising under any Company or Designated Subsidiary group insurance or benefit
program, travel expenses, business and moving reimbursements, income received in
connection with stock options,
<PAGE>
contributions made by the Company or a Designated Subsidiary under any employee
benefit plan, and similar items of compensation.

            (h)   "DATE OF EXERCISE" of any Option means the date on which such
Option is exercised, which shall be the last Trading Day of the Offering Period
with respect to which the Option was granted, in accordance with Section 4(a)
(except as provided in Section 9).

            (i)   "DATE OF GRANT" of any Option means the date on which such
Option is granted, which shall be the first Trading Day of the Offering Period
with respect to which the Option was granted, in accordance with Section 3(a).

            (j)   "DESIGNATED SUBSIDIARY" means any Subsidiary Corporation
designated by the Board in accordance with Section 13.

            (k)   "ELIGIBLE EMPLOYEE" means an Employee of the Company or any
Designated Subsidiary Corporation whose customary employment is for more than 5
months in any calendar year. In addition, Eligible Employee means an Employee
who does not, immediately after the Option is granted, own (directly or through
attribution) stock possessing five percent (5%) or more of the total combined
voting power or value of all classes of Stock or other stock of the Company, a
Parent Corporation or a Subsidiary Corporation (as determined under Section
423(b)(3) of the Code). For purposes of the foregoing, the rules of Section
424(d) of the Code with regard to the attribution of stock ownership shall apply
in determining the stock ownership of an individual, and stock which an Employee
may purchase under outstanding options shall be treated as stock owned by the
Employee.

            (l)   "EMPLOYEE" shall mean an individual who renders services to
the Company or a Subsidiary Corporation in the status of an "employee," within
the meaning of Code Section 3401(c). During a leave of absence meeting the
requirements of Treasury Regulation Section 1.421-7(h)(2), an individual shall
be treated as an Employee of the Company or Subsidiary Corporation employing
such individual immediately prior to such leave. "Employee" shall not include
any director of the Company or a Subsidiary Corporation who does not render
services to the Company or a Subsidiary Corporation in the status of an
"employee," within the meaning of Code Section 3401(c).

            (m)   "EXCHANGE ACT" means the Securities Exchange Act of 1934, as
amended.

            (n)   "OFFERING PERIOD" shall mean each calendar quarter during the
term of the Plan commencing on (1) any January 1 and ending on the subsequent
March 31, (2) commencing on any April 1 and ending on the subsequent June 30,
(3) commencing on any July 1 and ending on the subsequent September 30 or (4)
commencing on any October 1 and ending on any December 31. Options shall be
granted on the Date of Grant and exercised on the Date of Exercise, as provided
in Sections 3(a) and 4(a), respectively.

            (o)   "OPTION" means an option to purchase shares of Stock granted
under the Plan to a Participant in accordance with Section 3(a).

            (p)   "OPTION PRICE" means the option price per share of Stock
determined in accordance with Section 4(b).

            (q)   "PARENT CORPORATION" means any corporation, other than the
Company, in an unbroken chain of corporations ending with the Company if, at the
time of the granting of the Option, each of the corporations other than the
Company owns stock possessing 50% or more of

                                       2
<PAGE>
the total combined voting power of all classes of stock in one of the other
corporations in such chain.

            (r)   "PARTICIPANT" means an Eligible Employee who has elected to
participate in the Plan, in accordance with the provisions of Section 3(b).

            (s)   "PAYDAY" means the regular and recurring established day for
payment of Compensation to an Employee of the Company or any Subsidiary
Corporation.

            (t)   "PLAN" means the Stratagene Corporation Employee Stock
Purchase Plan.

            (u)   "STOCK" means the shares of the Company's Common Stock,
$0.0001 par value.

            (v)   "SUBSIDIARY CORPORATION" means any corporation, other than the
Company, in an unbroken chain of corporations beginning with the Company if, at
the time of the granting of the Option, each of the corporations other than the
last corporation in an unbroken chain owns stock possessing 50% or more of the
total combined voting power of all classes of stock in one of the other
corporations in such chain.

            (w)   "TRADING DAY" means a day on which the National Stock
Exchanges and the National Association of Securities Dealers Automated Quotation
(NASDAQ) System are open for trading.

      2.    STOCK SUBJECT TO THE PLAN. Subject to the provisions of Section 9
hereof (relating to adjustments upon changes in the Stock) and Section 11 hereof
(relating to amendments of the Plan), the Stock that may be sold pursuant to
Options granted under the Plan shall not exceed in the aggregate 1,000,000
shares of Stock. The shares of Stock sold pursuant to Options granted under the
Plan may be unissued shares or treasury shares of Stock, or shares reacquired in
private transactions or open market purchases. If and to the extent that any
right to purchase reserved shares shall not be exercised by any Participant for
any reason, or if such right to purchase shall terminate as provided herein,
shares that have not been so purchased hereunder shall again become available
for the purposes of this Plan, unless this Plan shall have been terminated, but
all shares sold under this Plan, regardless of source, shall be counted against
the limitation set forth above.

      3.    GRANT OF OPTIONS.

            (a)   Option Grants. The Company shall grant Options under the Plan
to all Participants in successive Offering Periods until the earlier of: (i) the
date on which the number of shares of Stock available under the Plan have been
sold, or (ii) the date on which the Plan is suspended or terminates. Each
Participant shall be granted an Option with respect to an Offering Period on the
Date of Grant. Each Option shall expire on the Date of Exercise immediately
after the automatic exercise of the Option in accordance with Section 4(a),
unless such Option terminates earlier in accordance with Section 5, 6 or 9. The
number of shares of Stock subject to a Participant's Option shall equal the
cumulative payroll deductions authorized by such Participant in accordance with
subsection (b) for the Offering Period (if any), divided by the Option Price;
provided, however, that the number of shares of Stock subject to such Option
shall not exceed 5,000; and, provided, further, that the number of shares of
Stock subject to such Option shall not exceed the number determined in
accordance with subsection (c). The Company shall not grant an Option with
respect to an Offering Period to any Participant who is not an Eligible Employee
on the first day of such Offering Period.

                                       3
<PAGE>
            (b)   Election to Participate; Payroll Deduction Authorization.
Except as provided in subsection (e), an Eligible Employee shall become a
Participant in the Plan only by means of payroll deduction. Each such
Participant who elects to participate in the Plan with respect to an Offering
Period shall deliver to the Company, not later than five (5) days before the
first day of the Offering Period, a completed and executed written payroll
deduction authorization in a form prepared by the Committee (the
"AUTHORIZATION"). Each Participant's Authorization shall give notice of such
Participant's election to participate in the Plan for the next following
Offering Period (and subsequent Offering Periods) and shall designate a whole
percentage of such Participant's Compensation to be withheld by the Company or
the Designated Subsidiary employing such Participant on each Payday during the
Offering Period. A Participant may designate any whole percentage of
Compensation which is not less than one percent (1%) and not more than fifteen
percent (15%). A Participant's Compensation payable during an Offering Period
shall be reduced each Payday through payroll deduction in an amount equal to the
percentage specified in the Authorization, and such amount shall be credited to
such Participant's Account under the Plan. A Participant may not increase or
decrease the percentage of Compensation designated in the Authorization or
suspend the Authorization during an Offering Period. Any Authorization shall
remain in effect for each subsequent Offering Period, unless the Participant
submits a new Authorization pursuant to this subsection (b), withdraws from the
Plan pursuant to Section 5, ceases to be an Eligible Employee as defined in
Section 1(k) or terminates employment as provided in Section 6. Notwithstanding
the foregoing, to the extent necessary to comply with Section 423(b)(8) of the
Code and Sections 3(a), (c) and (d) of the Plan, the Company may reduce a
Participant's rate of payroll deductions to zero at such time during any
Offering Period. Payroll deductions will recommence at the rate provided by the
Participant in his or her payroll deduction authorization to the extent such
payroll deductions may be applied to purchase shares of Stock in accordance with
Code Section 423(b)(8) and Sections 3(a), (c) and (d) of the Plan, unless
terminated by the Participant as provided in Section 5 of the Plan.

            (c)   $25,000 Limitation. No Participant shall be granted an Option
under the Plan which permits his rights to purchase shares of Stock under the
Plan, together with other options to purchase shares of Stock or other stock
under all other employee stock purchase plans of the Company, any Parent
Corporation or any Subsidiary Corporation subject to Section 423, to accrue at a
rate which exceeds $25,000 of fair market value of such shares of Stock or other
stock (determined at the time the Option or other option is granted) for each
calendar year in which the Option is outstanding. For purpose of the limitation
imposed by this subsection, (i) the right to purchase shares of Stock or other
stock under an Option or other option accrues when the Option or other option
(or any portion thereof) first becomes exercisable during the calendar year,
(ii) the right to purchase shares of Stock or other stock under an Option or
other option accrues at the rate provided in the Option or other option, but in
no case may such rate exceed $25,000 of the fair market value of such Stock or
other stock (determined at the time such Option or other option is granted) for
any one calendar year, and (iii) a right to purchase Stock or other stock which
has accrued under an Option or other option may not be carried over to any other
Option or other option. This limitation shall be applied in accordance with
Section 423(b)(8) of the Code and the Treasury Regulations thereunder.

            (d)   5 Percent Holders. No Employee will be granted an option under
this Plan if immediately after the grant, such Employee (or any other person
whose stock would be attributed to such Employee pursuant to Section 424(d) of
the Code) would own stock and/or hold outstanding options to purchase stock
possessing five percent (5%) or more of the total combined voting power or value
of all classes of stock of the Company or of any Subsidiary Corporation or
Parent Corporation.

                                       4
<PAGE>
      4.    EXERCISE OF OPTIONS; OPTION PRICE.

            (a)   Option Exercise. Each Participant automatically and without
any act on such Participant's part shall be deemed to have exercised such
Participant's Option on the Date of Exercise to the extent that the balance then
in the Participant's Account is sufficient to purchase, at the Option Price,
shares of the Stock subject to the Option, provided, however, that any balance
that is insufficient to purchase full shares of Stock shall be carried over to
the next Offering Period and shall remain credited to the Participant.

            (b)   Option Price Defined. The option price per share of Stock (the
"Option Price") to be paid by a Participant upon the exercise of the
Participant's Option shall be equal to 85% of the lesser of: (i) the Fair Market
Value of a share of Stock on the Date of Exercise and (ii) the Fair Market Value
of a share of Stock on the Date of Grant. The Fair Market Value of a share of
Stock as of a given date shall be: (A) the closing price of a share of Stock on
the principal exchange on which the Stock is then trading, if any, on the date
next preceding such date (or, if shares of Stock were not traded on such
preceding date, then on the next preceding trading day during which a sale
occurred); (B) if the Stock is not traded on an exchange, but is quoted on
Nasdaq or a successor quotation system, (I) the last sales price (if the Stock
is then listed as a National Market Issue under the NASD National Market
System), or (II) the mean between the closing representative bid and asked
prices (in all other cases) for a share of Stock on the date next preceding such
date (or, if shares of Stock were not traded on such preceding date, then on the
next preceding trading day during which a sale occurred) as reported by Nasdaq
or such successor quotation system; (iii) if the Stock is not publicly traded on
an exchange and not quoted on Nasdaq or a successor quotation system, the mean
between the closing bid and asked prices for a share of Stock on the date next
preceding such date (or, if shares of Stock were not traded on such preceding
date, then on the next preceding trading day during which a sale occurred), as
determined in good faith by the Committee; or (iv) if the Stock is not publicly
traded, the fair market value of a share of Stock established by the Committee
acting in good faith.

            (c)   Book Entry/Share Certificates. As soon as practicable after
the purchase of shares of Stock upon the exercise of an Option by a Participant,
the Company shall issue the shares of Stock to such Participant. The Company
shall make an entry on its books and records indicating that the shares of Stock
purchased in connection with such exercise have been duly issued as of that date
to such Participant. In the event the Company is required to obtain authority
from any commission or agency to issue any certificate or certificates for all
or a portion of the whole shares of Stock purchased hereunder, the Company shall
seek to obtain such authority as soon as reasonably practicable.

            (d)   Pro Rata Allocations. If the total number of shares of Stock
for which Options are to be exercised on any date exceeds the number of shares
of Stock remaining unsold under the Plan (after deduction for all shares of
Stock for which Options have theretofore been exercised), the Committee shall
make a pro rata allocation of the available remaining shares of Stock in as
nearly a uniform manner as shall be practicable and the balance of the amount
credited to the Account of each Participant which has not been applied to the
purchase of shares of Stock shall be paid to such Employee in one lump sum in
cash within thirty (30) days after the Date of Exercise, without any interest
thereon.

            (e)   Information Statement. The Company shall provide each
Participant whose Option is exercised with an information statement in
accordance with Section 6039(a) of the Code and the Treasury Regulations
thereunder. The Company shall maintain a procedure for identifying certificates
of shares of Stock sold upon the exercise of Options in accordance with Section
6039(b) of the Code.

                                       5
<PAGE>
      5.    WITHDRAWAL FROM THE PLAN.

            (a)   Withdrawal Election. A Participant may withdraw from
participation under the Plan at any time, except that a Participant may not
withdraw during the last five (5) days of any Offering Period. A Participant
electing to withdraw from the Plan must deliver to the Company a notice of
withdrawal in a form prepared by the Committee (the "WITHDRAWAL ELECTION"), not
later than five (5) days prior to the Date of Exercise for such Offering Period.
Upon receipt of a Participant's Withdrawal Election, the Company or Subsidiary
Corporation employing the Participant shall pay to the Participant the amount
credited to the Participant's Account in one lump sum payment in cash, without
any interest thereon, and the Company shall deliver to the Participant
certificates for any whole shares of Stock previously purchased by the
Participant which have not yet been delivered in accordance with Section 4(c),
in either case within thirty (30) days of receipt of the Participant's
Withdrawal Election. Upon receipt of a Participant's Withdrawal Election by the
Company, the Participant shall cease to participate in the Plan and the
Participant's Option for such Offering Period shall terminate.

            (b)   Eligibility following Withdrawal. A Participant who withdraws
from the Plan with respect to an Offering Period, and who is still an Eligible
Employee, may elect to participate again in the Plan for any subsequent Offering
Period by delivering to the Company an Authorization pursuant to Section 3(b).

      6.    TERMINATION OF EMPLOYMENT. If the employment of a Participant with
the Company or a Designated Subsidiary terminates for any reason, the
Participant's participation in the Plan automatically and without any act on the
Participant's part shall terminate as of the date of the termination of the
Participant's employment. As soon as practicable after such a termination of
employment, the Company or Designated Subsidiary employing the Participant shall
pay to the Participant (or the Participant's estate) the amount credited to the
Participant's Account in one lump sum payment in cash, without any interest
thereon, and the Company shall deliver to the Participant (or the Participant's
estate) certificates for any whole shares of Stock previously purchased by the
Participant which have not yet been delivered in accordance with Section 4(c).
Upon a Participant's termination of employment covered by this subsection, the
Participant's Authorization and Option under the Plan shall terminate.

      7.    RESTRICTION UPON ASSIGNMENT. An Option granted under the Plan shall
not be transferable other than by will or the laws of descent and distribution,
and is exercisable during the Participant's lifetime only by the Participant. An
Option may not be exercised to any extent except by the Participant. The Company
shall not recognize and shall be under no duty to recognize any assignment or
alienation of the Participant's interest in the Plan, the Participant's Option
or any rights under the Participant's Option.

      8.    NO RIGHTS OF STOCKHOLDERS UNTIL SHARES ISSUED. With respect to
shares of Stock subject to an Option, a Participant shall not be deemed to be a
stockholder of the Company, and the Participant shall not have any of the rights
or privileges of a stockholder, until such shares have been issued to the
Participant following exercise of the Participant's Option. No adjustments shall
be made for dividends (ordinary or extraordinary, whether in cash securities, or
other property) or distributions or other rights for which the record date
occurs prior to the date of such issuance, except as otherwise expressly
provided herein.

      9.    CHANGES IN THE STOCK AND CORPORATE EVENTS; ADJUSTMENT OF OPTIONS.

            (a)   Subject to Section 9(c), in the event that the Committee, in
its sole discretion, determines that any dividend or other distribution (whether
in the form of cash, Stock, other securities, or other property),
recapitalization, reclassification, stock split, reverse stock split,

                                       6
<PAGE>
reorganization, merger, consolidation, split-up, spin-off, combination,
repurchase, liquidation, dissolution, or sale, transfer, exchange or other
disposition of all or substantially all of the assets of the Company, or
exchange of Stock or other securities of the Company, issuance of warrants or
other rights to purchase Stock or other securities of the Company, or other
similar corporate transaction or event, affects the Stock such that an
adjustment is appropriate in order to prevent dilution or enlargement of the
benefits or potential benefits intended to be made available under the Plan or
with respect to an Option, then the Committee shall, in such manner as it may
deem equitable, adjust any or all of:

                  (i)   the number and kind of shares of Stock (or other
      securities or property) with respect to which Options may be granted
      (including, but not limited to, adjustments of the limitation in Section
      3(a) on the maximum number of shares of Stock which may be purchased),

                  (ii)  the number and kind of shares of Stock (or other
      securities or property) subject to outstanding Options, and

                  (iii) the exercise price with respect to any Option.

            (b)   Subject to Section 9(c), in the event of any transaction or
event described in Section 9(a) or any unusual or nonrecurring transactions or
events affecting the Company, any affiliate of the Company, or the financial
statements of the Company or any affiliate, or of changes in applicable laws,
regulations, or accounting principles, the Committee, in its sole discretion,
and on such terms and conditions as it deems appropriate, either by the terms of
the Option or by action taken prior to the occurrence of such transaction or
event and either automatically or upon the Participant's request, is hereby
authorized to take any one or more of the following actions whenever the
Committee determines that such action is appropriate in order to prevent
dilution or enlargement of the benefits or potential benefits intended to be
made available under the Plan or with respect to any Option under the Plan, to
facilitate such transactions or events or to give effect to such changes in
laws, regulations or principles:

                  (i)   To provide that all Options outstanding shall terminate
      without being exercised on such date as the Committee determines in its
      sole discretion;

                  (ii)  To provide that all Options outstanding shall be
      exercised prior to the Date of Exercise of such Options on such date as
      the Committee determines in its sole discretion and such Options shall
      terminate immediately after such exercise.

                  (iii) To provide for either the purchase of any Option
      outstanding for an amount of cash equal to the amount that could have been
      obtained upon the exercise of such Option had such Option been currently
      exercisable, or the replacement of such Option with other rights or
      property selected by the Committee in its sole discretion;

                  (iv)  To provide that such Option be assumed by the successor
      or survivor corporation, or a parent or subsidiary thereof, or shall be
      substituted for by similar options, covering the stock of the successor or
      survivor corporation, or a parent or subsidiary thereof, with appropriate
      adjustments as to the number and kind of shares and prices; and

                  (v)   To make adjustments in the number and type of shares of
      Stock (or other securities or property) subject to outstanding Options, or
      in the terms and conditions of outstanding Options, or Options which may
      be granted in the future.

                                       7
<PAGE>
            (c)   No adjustment or action described in this Section 9 or in any
other provision of the Plan shall be authorized to the extent that such
adjustment or action would cause the Plan to fail to satisfy the requirements of
Section 423 of the Code. Furthermore, no such adjustment or action shall be
authorized to the extent such adjustment or action would result in short-swing
profits liability under Section 16 of the Exchange Act, or violate the exemptive
conditions of Rule 16b-3 unless the Committee determines that the Option is not
to comply with such exemptive conditions. The number of shares of Common Stock
subject to any Option shall always be rounded up to the next whole number.

            (d)   The existence of the Plan and the Options granted hereunder
shall not affect or restrict in any way the right or power of the Company or the
stockholders of the Company to make or authorize any adjustment,
recapitalization, reorganization or other change in the Company's capital
structure or its business, any merger or consolidation of the Company, any issue
of stock or of options, warrants or rights to purchase stock or of bonds,
debentures, preferred or prior preference stocks whose rights are superior to or
affect the Stock or the rights thereof or which are convertible into or
exchangeable for Stock, or the dissolution or liquidation of the Company, or any
sale or transfer of all or any part of its assets or business, or any other
corporate act or proceeding, whether of a similar character or otherwise.

      10.   USE OF FUNDS; NO INTEREST PAID. All funds received or held by the
Company under the Plan shall be included in the general funds of the Company
free of any trust or other restriction and may be used for any corporate
purpose. No interest will be paid to any Participant or credited to any
Participant's Account with respect to such funds.

      11.   AMENDMENT, SUSPENSION OR TERMINATION OF THE PLAN. The Board may
amend, suspend, or terminate the Plan at any time and from time to time,
provided that approval by a vote of the holders of the outstanding shares of the
Company's capital stock entitled to vote shall be required to amend the Plan:
(a) to increase the number of shares of Stock that may be sold pursuant to
Options under the Plan, or (b) in any manner that would cause the Plan to no
longer be an "employee stock purchase plan" within the meaning of Section 423(b)
of the Code.

      12.   ADMINISTRATION BY COMMITTEE; RULES AND REGULATIONS.

            (a)   Appointment of Committee. The Plan shall be administered by
the Committee, which shall be composed of not less than two members of the
Board, each of whom shall be a "non-employee director" within the meaning of
Rule 16b-3 which has been adopted by the Securities and Exchange Commission
under the Exchange Act. Each member of the Committee shall serve for a term
commencing on a date specified by the Board and continuing until the member
dies, resigns or is removed from office by the Board. The Committee at its
option may utilize the services of an agent to assist in the administration of
the Plan, including establishing and maintaining an individual securities
account under the Plan for each Participant.

            (b)   Duties and Powers of Committee. It shall be the duty of the
Committee to conduct the general administration of the Plan in accordance with
the provisions of the Plan. The Committee shall have the power to interpret the
Plan and the terms of the Options and to adopt such rules for the
administration, interpretation, and application of the Plan as are consistent
therewith and to interpret, amend or revoke any such rules. In its absolute
discretion, the Board may at any time and from time to time exercise any and all
rights and duties of the Committee under the Plan.

            (c)   Sub-Plans. The Committee may adopt sub-plans applicable to
particular Designated Subsidiaries, which sub-plans may be designed to be
outside the scope of Code Section 423. The rules of such sub-plans may take
precedence over other provisions of this Plan,

                                       8
<PAGE>
with the exception of Section 2 above, but unless otherwise superseded by the
terms of such sub-plan, the provisions of this Plan shall govern the operation
of such sub-plan.

            (d)   Majority Rule. The Committee shall act by a majority of its
members in office. The Committee may act either by vote at a meeting or by a
memorandum or other written instrument signed by a majority of the Committee.

            (e)   Compensation; Professional Assistance; Good Faith Actions. All
expenses and liabilities incurred by members of the Committee in connection with
the administration of the Plan shall be borne by the Company. The Committee may,
with the approval of the Board, employ attorneys, consultants, accountants,
appraisers, brokers or other persons. The Committee, the Company and its
officers and directors shall be entitled to rely upon the advice, opinions or
valuations of any such persons. All actions taken and all interpretations and
determinations made by the Committee in good faith shall be final and binding
upon all Participants, the Company and all other interested persons. No member
of the Committee shall be personally liable for any action, determination or
interpretation made in good faith with respect to the Plan or the Options, and
all members of the Committee shall be fully protected by the Company in respect
of any such action, determination, or interpretation.

      13.   DESIGNATION OF SUBSIDIARY CORPORATIONS. The Board shall designate
from among the Subsidiary Corporations, as determined from time to time, the
Subsidiary Corporation or Subsidiary Corporations whose Employees shall be
eligible to be granted Options under the Plan. The Board may designate a
Subsidiary Corporation, or terminate the designation of a Subsidiary
Corporation, without the approval of the stockholders of the Company.

      14.   NO RIGHTS AS AN EMPLOYEE. Nothing in the Plan shall be construed to
give any person (including any Participant) the right to remain in the employ of
the Company, a Parent Corporation or a Subsidiary Corporation or to affect the
right of the Company, any Parent Corporation or any Subsidiary Corporation to
terminate the employment of any person (including any Participant) at any time,
with or without cause.

      15.   TERM; APPROVAL BY STOCKHOLDERS. Subject to approval by the
stockholders of the Company in accordance with this Section, the Plan shall be
in effect until __________, 2014. No Option may be granted during any period of
suspension of the Plan or after termination of the Plan. The Plan shall be
submitted for the approval of the Company's stockholders within twelve (12)
months after the date of the adoption of the Plan by the Board. Options may be
granted prior to such stockholder approval; provided, however, that such Options
shall not be exercisable prior to the time when the Plan is approved by the
Company's stockholders; and, provided, further, that if such approval has not
been obtained by the end of said 12-month period, all Options previously granted
under the Plan shall thereupon terminate without being exercised.

      16.   EFFECT UPON OTHER PLANS. The adoption of the Plan shall not affect
any other compensation or incentive plans in effect for the Company, any Parent
Corporation or any Subsidiary Corporation. Nothing in this Plan shall be
construed to limit the right of the Company, any Parent Corporation or any
Subsidiary Corporation to: (a) establish any other forms of incentives or
compensation for employees of the Company, any Parent Corporation or any
Subsidiary Corporation or (b) grant or assume options otherwise than under the
Plan in connection with any proper corporate purpose, including, but not by way
of limitation, the grant or assumption of options in connection with the
acquisition, by purchase, lease, merger, consolidation or otherwise, of the
business, stock or assets of any corporation, firm or association.

                                       9
<PAGE>
      17.   CONDITIONS TO ISSUANCE OF STOCK CERTIFICATES. The Company shall not
be required to issue or deliver any certificate or certificates for shares of
Stock purchased upon the exercise of Options prior to fulfillment of all the
following conditions:

            (a)   The admission of such shares to listing on all stock
exchanges, if any, on which the Stock is then listed; and

            (b)   The completion of any registration or other qualification of
such shares under any state or federal law or under the rulings or regulations
of the Securities and Exchange Commission or any other governmental regulatory
body, which the Committee shall, in its absolute discretion, deem necessary or
advisable; and

            (c)   The obtaining of any approval or other clearance from any
state or federal governmental agency which the Committee shall, in its absolute
discretion, determine to be necessary or advisable; and

            (d)   The payment to the Company of all amounts which it is required
to withhold under federal, state or local law upon exercise of the Option; and

            (e)   The lapse of such reasonable period of time following the
exercise of the Option as the Committee may from time to time establish for
reasons of administrative convenience.

      18.   NOTIFICATION OF DISPOSITION. Each Participant shall give prompt
notice to the Company of any disposition or other transfer of any shares of
Stock purchased upon exercise of an Option if such disposition or transfer is
made: (a) within two (2) years from the Date of Grant of the Option, or (b)
within one (1) year after the transfer of such shares of Stock to such
Participant upon exercise of such Option. Such notice shall specify the date of
such disposition or other transfer and the amount realized, in cash, other
property, assumption of indebtedness or other consideration, by the Participant
in such disposition or other transfer.

      19.   NOTICES. Any notice to be given under the terms of the Plan to the
Company shall be addressed to the Company in care of its Secretary and any
notice to be given to any Participant shall be addressed to such Participant at
such Participant's last address as reflected in the Company's records. By a
notice given pursuant to this Section, either party may designate a different
address for notices to be given to it, him or her. Any notice which is required
to be given to a Participant shall, if the Participant is then deceased, be
given to the Participant's personal representative if such representative has
previously informed the Company of his status and address by written notice
under this Section. Any notice shall have been deemed duly given if enclosed in
a properly sealed envelope or wrapper addressed as aforesaid at the time it is
deposited (with postage prepaid) in a post office or branch post office
regularly maintained by the United States Postal Service.

      20.   ADDITIONAL RESTRICTIONS OF RULE 16B-3. The terms and conditions of
options granted hereunder to, and the purchase of shares by, persons subject to
Section 16 of the Exchange Act will comply with the applicable provisions of
Rule 16b-3. This Plan will be deemed to contain, and such options will contain,
and the shares issued upon exercise thereof will be subject to, such additional
conditions and restrictions as may be required by Rule 16b-3 to qualify for the
maximum exemption from Section 16 of the Exchange Act with respect to Plan
transactions.

                                       10
<PAGE>
      21.   EQUAL RIGHTS AND PRIVILEGES. All Eligible Employees of the Company
(or of any Designated Subsidiary) will have equal rights and privileges under
this Plan so that this Plan qualifies as an "employee stock purchase plan"
within the meaning of Section 423 of the Code or applicable Treasury regulations
thereunder. Any provision of this Plan that is inconsistent with Section 423 or
applicable Treasury regulations will, without further act or amendment by the
Company or the Board, be reformed to comply with the equal rights and privileges
requirement of Section 423 or applicable Treasury regulations.

      22.   HEADINGS. Headings are provided herein for convenience only and are
not to serve as a basis for interpretation or construction of the Plan.

                                 * * * * * * *

            I hereby certify that the Stratagene Corporation Employee Stock
Purchase Plan was adopted by the Board of Directors of Stratagene Corporation on
___________, 2004.

            Executed at _____________, California on this ___ day of
___________, 2004.

__________________________________________
Secretary

                                 * * * * * * *

            I hereby certify that the Stratagene Corporation Employee Stock
Purchase Plan was approved by the stockholders of Stratagene Corporation on
__________, 2004.

            Executed at _____________, California on this ___ day of
___________, 2004.

__________________________________________
Secretary

                                       11<PAGE>
                                                                   EXHIBIT 10.10

                            THERMAL CYCLER SUPPLIER
                            AUTHORIZATION AGREEMENT

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
<PAGE>

                            THERMAL CYCLER SUPPLIER
                            AUTHORIZATION AGREEMENT

        This Agreement ("Agreement"), effective January 1, 1995 ("Effective
Date"), is made by and between The Perkin-Elmer Corporation, a New York
corporation having an office at 761 Main Avenue, Norwalk, Connecticut 06859
("Perkin-Elmer"), and Stratagene, a California corporation having an office at
11011 North Torrey Pines Road, La Jolla, California 92037 ("Thermal Cycler
Supplier"), referred to collectively herein as the "Parties".

        Whereas, Perkin-Elmer has the power to convey limited rights for
research and in certain other fields under U.S. Patent Nos. 4,683,195,
4,683,202 and 4,965,188, describing and claiming gene amplification processes,
including a process known as the polymerase chain reaction ("PCR") process,
which are owned by Hoffman-La Roche Inc., and corresponding counterpart patents
and patent applications in other countries, which are owned by F. Hoffmann-La
Roche Ltd (both of which are referred to collectively herein as "Roche").

        Whereas, Perkin-Elmer offers to PCR users commercial and non-commercial
license rights under these patents and patent applications for automated
performance of the PCR process for research and certain other fields that
include, inter alia, an up-front fee component based on the capacity of thermal
cyclers used to perform the process.

        Whereas, Perkin-Elmer offers to suppliers of thermal cyclers certain
license rights under those patents, namely, an authorization to sell and
distribute their instruments with a label conveying to their customers rights
under the up-front fee component of the PCR licenses described above, and the
right to promote their instruments as "Authorized Thermal Cyclers" for PCR.

         Whereas, Perkin-Elmer also has the power to convey limited license
rights under U.S. Patent Nos. 5,038,852 and 5,333,675, describing and claiming
automated apparatus suitable for performing the PCR process, any apparatus
claim issuing from an application claiming priority of U.S. application

                                      -1-
<PAGE>

Serial No. 833,368 or U.S. application Serial No. 899,061 (both filed in 1986)
and apparatus claims in corresponding counterpart patents and patent
applications in other countries ("PCR Instrument Patents").

     WHEREAS, Perkin-Elmer offers the above process rights and apparatus rights
separately or in combination and, Thermal Cycler Supplier has requested PCR
process license rights only, without rights under any apparatus claims.

         NOW, THEREFORE, the Parties agree as follows:

         1.    DEFINITIONS

         1.1 "AMPLIFICATION PATENT RIGHTS" shall mean the nucleic acid
amplification processes, including particularly the PCR process, covered by:
United States Patent Nos. 4,683,195, 4,683,202 and 4,695,188; any amplification
process claim issuing from an application claiming priority of U.S. application
Serial No. 833,368 or U.S. application Serial No. 899,061 (both filed in 1986);
and any corresponding amplification process claim in patents and patent
applications in other countries claiming priority of any of them.

        1.2 "AUTHORIZED REAGENT" shall mean a DNA polymerase whose use in
performance of the PCR process is covered by the running-royalty component of a
PCR process license for internal research and development. The running-royalty
component of that license may be obtained through the purchase of reagents
bearing a valid label conveying the running-royalty component; alternatively, it
may be purchased from Perkin-Elmer. Other PCR process licenses in the Fields
also require use of Authorized Reagents.

        1.3 "AUTHORIZED THERMAL CYCLER" shall mean a thermal cycler or
temperature cycling instrument whose use in automated performance of the PCR
process is covered by the up-front fee component of a PCR process license for
internal research and development. The up-front fee component of that license
may be obtained through the purchase of a thermal cycler or temperature

                                      -2-
<PAGE>

cycling instrument bearing a valid label conveying the up-front component;
alternatively, it may be purchased from Perkin-Elmer. Other PCR process licenses
in the Fields also require use of an instrument whose use is similarly covered,
i.e., an 'Authorized Thermal Cycler".

         1.4 "FIELDS" shall mean research and development, quality assurance or
control, environmental testing, plant diagnostics, identity testing (other than
parentage testing for humans) and forensics.

         1.5   "TERRITORY" shall mean worldwide.

         1.6   "THIRD PARTY" shall mean a party other than the Parties.

         2. GRANT

         2.1 Upon the terms and subject to the exceptions and conditions of this
Agreement, Perkin-Elmer grants to Thermal Cycler Supplier the following
personal, non-transferable, royalty-bearing, non-exclusive rights in the
Territory under the Amplification Patent Rights:

         (a) Thermal Cycler Supplier is hereby authorized to sell and distribute
to end users, directly or through its distributors and under Thermal Cycler
Supplier's name and trademarks, thermal cyclers and temperature cycling
instruments manufactured by Thermal Cycler Supplier or manufactured for Thermal
Cycler Supplier for sale under its name and trademarks, but not otherwise to
sell or distribute to thermal cycler suppliers, with a label conveying to end
users (including Thermal Cycler Supplier itself) in the Fields the up-front
rights of PCR process licenses as specified in the label set forth in Section
5.1 below, that is, with an Authorized Thermal Cycler label; and

         (b) Thermal Cycler Supplier may advertise and promote thermal cyclers
and temperature cycling instruments so labeled as Authorized Thermal Cyclers for
PCR.

                                      -3-
<PAGE>

         2.2 No right, immunity, authorization or license is granted under this
Agreement, expressly or by implication, under any apparatus claim of any patent
or patent application owned by or licensed to Perkin-Elmer or Roche. Neither
this Agreement nor any grant hereunder shall affect the rights of the Parties
with respect to any such claim vis-a-vis any thermal cycler or temperature
cycling instrument, or the enforcement of those rights.

         2.3 No right, immunity, authorization or license is granted under this
Agreement, expressly or by implication, for any other purpose, or in any other
field, including: to make, have made, use or sell any polymerase amplification
reagent or kit; or to perform PCR or nucleic acid amplification that is not
fully licensed under the Amplification Patent Rights. No right, immunity,
authorization or license is granted under this Agreement, expressly or by
implication, under any patent or patent application not expressly included in
Amplification Patent Rights.

         2.4 Rights granted to Thermal Cycler Supplier by this Agreement are
personal to Thermal Cycler Supplier alone. Thermal Cycler Supplier shall have no
right to sublicense, assign or otherwise transfer or share it rights hereunder.
Notwithstanding the foregoing, Thermal Cycler Supplier may exercise its right to
market, sell and distribute under Section 2.1 through independent distributors.

         3. FEES, ROYALTIES, RECORDS AND REPORTS

         3.1 For the authorization rights granted under Article 2, Thermal
Cycler Supplier shall pay to Perkin-Elmer: a license issue fee of $*** plus,
for each thermal cycler or temperature cycling instrument delivered of invoiced
by the Thermal Cycler Supplier after the Effective Date of this Agreement, a
royalty payment as follows,

         (a) for calendar year 1995: $*** for a capacity of up to *** samples
plus $*** for each additional *** samples or part thereof:

        Payment($) = *** + *** x (maximum sample capacity - ***)/***,

         where the calculated fraction, (maximum sample capacity - ***)/***, is
rounded to the next higher whole number; and,

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

                                      -4-
<PAGE>

         (b) from January 1, 1996: $*** for a capacity of up to *** samples plus
$*** for each additional *** samples or part thereof;

         Payment($) = *** + *** x (maximum sample capacity - ***)/***,

         where the calculated fraction, (maximum sample capacity - ***)/***, is
rounded to the next higher whole number.

The license issue fee shall be due and owing and shall be paid on execution of
this Agreement. The per-thermal cycler fees shall be paid as specified in
Sections 3.4 and 3.5. Each instrument for which that fee is paid shall be an
Authorized Thermal Cycler and shall be so designated pursuant to Article 5
hereof.

         3.2 All amounts payable hereunder shall be payable in United States
dollars.

         3.3 Thermal Cycler Supplier shall keep full true and accurate books of
account containing all particulars necessary to show the amount payable to
Perkin-Elmer under this Agreement. Such books and the supporting data shall be
open at all reasonable times, for three (3) years following the end of the
calendar year to which they pertain (and access shall not be denied thereafter,
if reasonably available), to the inspection of an independent inspector retained
by Perkin-Elmer. If in dispute, such records shall be kept until the dispute is
settled. Inspection shall be at Perkin-Elmer's expense, unless the inspector
concludes that the amount payable that is stated in a report is understated by
five percent (5%) or more, in which case expenses shall be paid by Thermal
Cycler Supplier.

         3.4 Thermal Cycler Supplier shall within thirty (30) days after the
first of each January, April, July and October deliver to Perkin-Elmer a true
and accurate accounting report. This report shall give such particulars of the
business conducted by Thermal Cycler Supplier during the preceding three (3)
calendar months as are pertinent to accounting under this Agreement and shall be
in accordance with, and include all information specified in, the royalty report
form attached hereto as Appendix A.

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

                                      -5-
<PAGE>

         The correctness and completeness of each report shall be attested to in
writing by the responsible financial officer of Thermal Cycler Supplier or by
Thermal Cycler Supplier's external auditor.

         3.5 Simultaneously with the delivery of each royalty report, Thermal
Cycler Supplier shall pay to Perkin-Elmer the monies then due under this
Agreement for the period covered by the report. Each report and payment shall be
sent by the due date to the following address:

                         Applied Biosystems Division
                         The Perkin-Elmer Corporation
                         850 Lincoln Centre Drive
                         Foster City, California, U.S.A. 94404
                         Attention: Director of Licensing

or to any address that Perkin-Elmer may advise in writing.

         3.6 If Thermal Cycler Supplier shall fail to pay any amount owing under
this Agreement by the due date, the amount owed shall bear interest at two
percent (2%) over the Citibank NA base lending rate ("prime rate") from the due
date until paid, provided, however, that if this interest rate is held to be
unenforceable for any reason, the interest rate shall be the maximum rate
allowed by law at the time the payment is due.

         3.7 Failure of Thermal Cycler Supplier to pay any amount specified
under this Agreement within thirty (30) days after the due date will give
Perkin-Elmer the right to terminate under Section 6.7.

         4. PAST SALES AND ACTIVITIES

         4.1 Upon execution of this Agreement Thermal Cycler Supplier shall pay
to Perkin-Elmer the sum of $*** which shall be due and owing on that date.
In consideration therefor all thermal cyclers delivered or invoiced by Thermal
Cycler Supplier prior to the Effective Date of this Agreement shall be
considered Authorized Thermal Cyclers, subject to the conditions of Sections 4.2

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

                                      -6-
<PAGE>

and 5.3; and all earlier use of such thermal cyclers by customers, direct or
indirect, of Thermal Cycler Supplier shall be deemed to have been use of a
thermal cycler within the grant of this Agreement.

         4.2 Thermal Cycler Supplier shall send to the original end-user
customers of the thermal cyclers that are the subject of Section 3.1 or Section
4.1 but were shipped without labels specified in Section 5.1 Authorized Thermal
Cycler notices in accordance with Section 5.1 with a means reasonably
satisfactory to Perkin-Elmer to relate each such notice to the appropriate
thermal cycler. Any such thermal cycler not having an authorization notice by
July 31, 1995 shall cease to be an Authorized Thermal Cycler unless Thermal
Cycler Supplier establishes to the reasonable satisfaction of Perkin-Elmer that
(a) the thermal cycler falls within Section 4.1 and (b) the Authorized Thermal
Cycler notice for the thermal cycler has not been applied to another instrument.

         5. AUTHORIZATION NOTICE

         5.1 Thermal Cycler Supplier agrees to include in the front of the
user's manual for each Authorized Thermal Cycler, and for no other thermal
cycler, a Notice as specified from time to time by Perkin-Elmer. Unless and
until Perkin-Elmer reasonably instructs differently, the Notice shall be:

                            AUTHORIZED THERMAL CYCLER

               THIS INSTRUMENT, SERIAL NO.____, IS IN AUTHORIZED THERMAL CYCLER.
               ITS PURCHASE PRICE INCLUDES THE UP-FRONT FEE COMPONENT OF A
               LICENSE UNDER THE PATENTS ON THE POLYMERASE CHAIN REACTION (PCR)
               PROCESS, WHICH ARE OWNED BY HOFFMANN-LA ROCHE INC. AND F.
               HOFFMANN-LA ROCHE LTD, TO PRACTICE THE PCR PROCESS FOR INTERNAL
               RESEARCH AND DEVELOPMENT USING THIS INSTRUMENT. THE
               RUNNING-ROYALTY COMPONENT OF THAT LICENSE MAY BE PURCHASED FROM
               PERKIN-ELMER OR OBTAINED BY PURCHASING AUTHORIZED REAGENTS. THIS
               INSTRUMENT IS ALSO AN AUTHORIZED THERMAL CYCLER FOR USE WITH
               APPLICATIONS LICENSES AVAILABLE FROM PERKIN-ELMER. ITS USE WITH
               AUTHORIZED REAGENTS ALSO PROVIDES A LIMITED PCR LICENSE IN
               ACCORDANCE WITH THE LABEL RIGHTS ACCOMPANYING SUCH REAGENTS.
               PURCHASE OF THIS PRODUCT DOES NOT ITSELF CONVEY TO THE PURCHASER
               A COMPLETE LICENSE OR RIGHT TO PERFORM THE PCR PROCESS. FURTHER
               INFORMATION ON PURCHASING LICENSES TO PRACTICE THE PCR PROCESS
               MAY BE OBTAINED BY CONTACTING THE DIRECTOR OF LICENSING AT THE
               PERKIN-ELMER CORPORATION, 850 LINCOLN CENTRE DRIVE, FOSTER CITY,
               CALIFORNIA 94404.

               PERKIN-ELMER DOES NOT GUARANTEE THE PERFORMANCE OF THIS
               INSTRUMENT.

                                      -7-
<PAGE>

         5.2 Thermal Cycler Supplier agrees to affix permanently and prominently
to each Authorized Thermal Cycler the designation "Authorized Thermal Cycler,"
its Serial Number and a direction to consult the user's manual for license
information.

         5.3 Thermal Cycler Supplier further agrees to instruct the ultimate
purchaser that transfer of the thermal cycler without the Serial Number or the
Notice shall automatically terminate the authorization granted by this Agreement
and the thermal cycler shall cease to be an Authorized Thermal Cycler.

         5.4 To avoid confusion among thermal cycler users, Thermal Cycler
Supplier agrees not to designate or refer to its Authorized Thermal Cyclers as
"licensed" under the Amplification Patent Rights or "licensed" for PCR. However,
Perkin-Elmer agrees that Thermal Cycler Supplier may designate or refer to its
Authorized Thermal Cyclers as carrying up-front license rights under the
Amplification Patent Rights in a manner that fairly does not suggest that use of
an Authorized Thermal Cycler conveys a full license under the Amplification
Patent Rights.

         6. TERM AND TERMINATION

         6.1 This Agreement, unless sooner terminated, shall continue until the
expiration of the last-to-expire of the Amplification Patent Rights.

         6.2 This Agreement shall terminate upon a holding of invalidity or
unenforceability of all claims of the Amplification Patent Rights by a final
court decision from which no appeal is or can be taken.

         6.3 Thermal Cycler Supplier may terminate this Agreement for any reason
by giving written notice to Perkin-Elmer and ceasing to advertise or promote its
thermal cyclers as Authorized Thermal Cyclers. Such termination shall be
effective ninety (90) days after said notice or cessation, whichever is later.

                                      -8-
<PAGE>

         6.4 The decision of a Court or Administrative body finding Perkin-Elmer
liable or culpable due to Thermal Cycler Supplier's manufacture, sale or
distribution of Authorized Thermal Cyclers shall give Perkin-Elmer the right to
terminate this Agreement immediately upon notice.

         6.5 This Agreement shall terminate upon (i) an adjudication of Thermal
Cycler Supplier as bankrupt or insolvent, or Thermal Cycler Supplier's admission
in writing of its inability to pay its obligations as they mature; (a) an
assignment by Thermal Cycler Supplier for the benefit of creditors; (iii) the
appointment of, or Thermal Cycler Supplier's applying for or consenting to the
appointment of a receiver, trustee or similar officer for a substantial part of
its property; (iv) the institution of or any act of Thermal Cycler Supplier
instituting any bankruptcy, insolvency arrangement, or similar proceeding; (v)
the issuance or levy of any judgment, writ, warrant of attachment or execution
or similar process against a substantial part of the property of Thermal Cycler
Supplier; or (vi) loss of Thermal Cycler Suppliers federal or state licenses,
permits or accreditation necessary for distribution of Authorized Thermal
Cyclers.

         6.6 Perkin-Elmer may terminate this Agreement immediately on notice
upon any change in the ownership or control of Thermal Cycler Supplier or of its
assets. For such purposes, a "change in ownership or control" shall mean that
***% or more of the voting stock of Thermal Cycler Supplier becomes subject to
the ownership or control of a person or entity, or any related group of persons
or entities acting in concert, which person(s) or entity(ies) did not own or
control any portion of the voting stock on the Effective Date hereof.
Perkin-Elmer shall have the same right to terminate upon any transfer of ***% or
more of the assets of Thermal Cycler Supplier. Thermal Cycler Supplier warrants
that no portion of its voting stock was owned on the Effective Date hereof by
any instrument manufacturer or biotechnology company.

         6.7 Upon any breach of or default of a material term under this
Agreement by Thermal Cycler Supplier, Perkin-Elmer may terminate this Agreement
upon thirty (30) days' written notice. Perkin-Elmer will withdraw such notice
if, during the notice period, Thermal Cycler Supplier fully cures such breach or
default to Perkin-Elmer's reasonable satisfaction.

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

                                      -9-
<PAGE>
        6.8 Upon expiration or termination of this Agreement, all rights granted
to Thermal Cycler Supplier shall revert to or be retained by Perkin-Elmer.

        6.9 Thermal Cycler Supplier's obligations to report and pay royalties as
to activities under the Agreement shall survive termination or expiration.

        7. CONFIDENTIALITY - PUBLICITY

        7.1 In advertisements, catalogs, brochures, sales literature and
promotional literature for Authorized Thermal Cyclers, Thermal Cycler Supplier
shall state the following prominently in type and location:

               Practice of the patented polymerase chain reaction (PCR) process
               requires a license. Stratagene's thermal cycler is an Authorized
               Thermal Cycler. Its use with Authorized Reagents provides a
               limited PCR license in accordance with the label rights
               accompanying such reagents. It may also be used with PCR licenses
               available from The Perkin-Elmer Corporation.

        7.2 With respect to Thermal Cycler Supplier's distribution of any
written information to Third Parties, including but not limited to advertising,
brochures, catalogs, promotional and sales material, and public relations
material, Perkin-Elmer shall have the right to prescribe changes regarding
references to, or descriptions of: Perkin-Elmer, PCR, the Amplification Patent
Rights, the PCR Instrument Patents, PCR licenses or authorizations, or this
Agreement. Thermal Cycler Supplier agrees to comply with Perkin-Elmer's
reasonable prescriptions.

        7.3 Except as provided in Sections 7.1 and 7.2, Thermal Cycler Supplier
shall, to the extent reasonably practicable, maintain the confidentiality of the
provisions of this Agreement and shall refrain from disclosing the terms of this
Agreement without the prior written consent of Perkin-Elmer, except to the
extent Thermal Cycler Supplier concludes in good faith that such disclosure is
required under applicable law or regulation, in which case Perkin-Elmer shall be
notified in advance.

                                      -10-
<PAGE>

        8. COMPLIANCE AND QUALITY

        8.1 In the exercise of any and all rights and in performance hereunder,
it shall be the duty of the Thermal Cycler Supplier, not Perkin-Elmer, to
comply fully with all applicable laws, regulations and ordinances and to obtain
and keep in affect licenses, permits and other governmental approvals (federal,
state or local) necessary or appropriate to carry on activities hereunder.

        8.2 Perkin-Elmer does not approve or endorse thermal cyclers of Thermal
Cycler Supplier in any way or for any purpose, including PCR. Quality and
quality control with respect to suitability for PCR, according to standards and
requirements that may exist in the marketplace from time to time, are the sole
responsibility of Thermal Cycler Supplier.

        9. ASSIGNMENT

        9.1 This Agreement shall not be assigned by Thermal Cycler Supplier
(including without limitation any assignment or transfer that would arise from a
sale or transfer of Thermal Cycler Supplier's business).

        9.2 Perkin-Elmer may assign all or any part of its rights and
obligations under this Agreement at any time without the consent of Thermal
Cycler Supplier. Thermal Cycler Supplier agrees to execute such further
acknowledgments or other instruments as Perkin-Elmer may reasonably request in
connection with such assignment.

        10. NEGATION OF WARRANTIES AND INDEMNITY

        10.1 Nothing in this Agreement shall be construed as: (a) a warranty or
representation by Perkin-Elmer as to the validity or scope of any patent; (b) a
warranty or representation that the practice under the Amplification Patent
Rights is or will be free from infringement of patents of Third Parties; (c) an
authority or obligation to sublicense or to sue Third Parties for infringement;
(d) except as expressly set forth herein, conferring the right to use in
advertising, publicity or otherwise, in any form, the name of, or any trademark
or trade name of, Perkin-Elmer or Roche; (e) conferring

                                      -11-
<PAGE>

by implication, estoppel or otherwise any license, immunity or right under any
patent owned by or licensed to Perkin-Elmer or Roche other than those specified,
regardless of whether such patent is dominant or subordinate to the
Amplification Patent Rights; (f) an obligation to furnish any know-how; or (g)
creating any agency, partnership, joint venture or similar relationship between
Perkin-Elmer or Roche and Thermal Cycler Supplier.

        10.2 PERKIN-ELMER MAKES NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

        10.3 Thermal Cycler Supplier agrees to take all reasonable precautions
to prevent death, personal injury, illness and property damage from the use of
Authorized Thermal Cyclers. Thermal Cycler Supplier shall assume full
responsibility for its operation under the Amplification Patent Rights, the
manufacture of Authorized Thermal Cyclers and the use thereof and shall defend,
indemnify and hold Perkin-Elmer harmless from and against all liability,
demands, damages, expenses (including attorneys' fees) and losses for death,
personal injury, illness, property damage or any other injury or damage,
including any damages or expenses arising in connection with state or federal
regulatory action, in view of the use by Thermal Cycler Supplier, its officers,
directors, agents and employees of the Amplification Patent Rights, and the
manufacture and use of Authorized Thermal Cyclers except that Thermal Cycler
Supplier shall not be liable to Perkin-Elmer for injury or damage arising solely
out of or resulting from Perkin-Elmer's negligence, willful conduct or
intentional acts or intentional omissions with respect to a Perkin-Elmer-
supplied product.

        11. MOST FAVORED LICENSEE

        11.1 If after signature of this Agreement (a) Perkin-Elmer grants to any
unrelated Third Party thermal cycler supplier other than Roche a license of the
instant type, that is, a Thermal Cycler Supplier Authorization Agreement
granting rights only under the Amplification Patent Rights, or a license of the
type previously offered to Thermal Cycler Supplier, that is, a Thermal Cycler
Supplier Agreement granting rights under the Amplification Patent Rights and the
PCR Instrument Patents but which includes therein a per thermal cycler royalty
payment only under the Amplification Patent

                                      -12-
<PAGE>

Rights, and (b) the grant only under the Amplification Patent Rights is of
substantially the same scope as granted to Thermal Cycler Supplier herein
***, then Perkin-Elmer shall promptly notify Thermal Cycler Supplier of ***, and
Thermal Cycler Supplier shall have the right and option to ***. Thermal Cycler
Supplier's right to *** shall extend only for so long as and shall be
conditioned on Thermal Cycler Supplier's acceptance of all the conditions,
favorable or unfavorable, applicable to rights under only the Amplification
Patent Rights under which ***.  Upon Thermal Cycler Supplier's acceptance of
***, the *** shall be effective as to Thermal Cycler Supplier on the date of
***.

        11.2 If within *** after signature of this Agreement, Perkin-Elmer
grants to any unrelated Third Party thermal cycler supplier other than Roche a
license under the Amplification Patent Rights only and of substantially the same
scope as granted to Thermal Cycler Supplier hereunder ***, Perkin-Elmer shall
promptly notify Thermal Cycler Supplier of ***, and Thermal Cycler Supplier
shall have the right and option, exercisable within ninety (90) days of
notification, to ***. Thermal Cycler Supplier's right to *** shall extend only
for so long as and shall be conditioned on Thermal Cycler Supplier's acceptance
of all the same conditions, favorable or unfavorable, exclusive of payment for
the past, under which *** shall be available to such other Third Party. If
Thermal Cycler Supplier elects to ***, Thermal Cycler Supplier shall receive
credit for the license issue fee paid hereunder.  Other financial terms shall
apply to financial obligations incurred by Thermal Cycler Supplier after the
date of ***.

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                      -13-
<PAGE>

        11.3 If after signature of this Agreement, Perkin-Elmer grants to an
unrelated Third Party thermal cycler supplier other than Roche a license of the
type previously offered to Thermal Cycler Supplier, that is, a Thermal Cycler
Supplier Agreement granting combined rights under the Amplification Patent
Rights and the PCR Instrument Patents ("Combined License"), ***, then
Perkin-Elmer shall promptly notify Thermal Cycler Supplier of the *** and the
*** therefor, and Thermal Cycler Supplier shall have the right and option,
exercisable within *** after notification, to ***, retroactive to the Effective
Date of this Agreement, as follows: Thermal Cycler Supplier shall receive credit
for all payments made hereunder; all financial obligations of Thermal Cycler
Supplier shall be recalculated according to the ***, and payment for the past,
exclusive of any credit, shall be ***.

        11.4 None of Section 11.1 through 11.3 shall apply to a Third Party
grant or license for which Perkin-Elmer and/or Roche shall ***, for example,
such as ***, as part of the ***.

        12. GENERAL

        12.1 This Agreement constitutes the entire agreement between the Parties
as to the subject matter hereof, and all prior negotiations, representations,
agreements and understandings are merged into, extinguished by and completely
expressed by it. This Agreement may be modified or amended only by a writing
executed by authorized officers of each of the Parties.

        12.2 Any notice required or permitted to be given by this Agreement
shall be given by postpaid, first class, registered or certified mail, or by
courier or facsimile, property addressed to the other party at the respective
address as shown below:

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                      -14-
<PAGE>

If to Perkin-Elmer:

                        Applied Biosystems Division
                        The Perkin-Elmer Corporation
                        850 Lincoln Centre Drive
                        Foster City, California U.S.A. 94404
                        Att'n.: Director of Licensing

If to Thermal Cycler Supplier:

                        Stratagene
                        11011 North Torrey Pines Road
                        La Jolla, California U.S.A. 92037
                        Att'n.: Chief Executive Officer

Either party may change its address by providing notice to the other. A notice
shall be deemed given four (4) full business days after the day of mailing, or
one full day after the date of delivery to the courier, or the date of facsimile
transmission, as the case may be.

        12.3 Governing Law and Venue. This Agreement shall be deemed made in the
County and State of New York, and it shall be construed and enforced in
accordance with the law of the State of New York. The Parties agree that the
exclusive jurisdiction and venue for any dispute or controversy arising from
this Agreement shall be in the state or federal courts in New York.

        12.4 Arbitration

        (a) If arbitration is demanded within the applicable statute of
limitations for commencement of an action in a New York court, disputes
concerning solely the determination of certain facts shall be settled by final
and binding arbitration at a mutually convenient location in the State of New
York pursuant to the commercial arbitration rules of the American Arbitration
Association in accordance with the following procedure: the arbitration tribune
shall consist of three arbitrators, one selected by each party and the third,
the chairman, selected by those two within sixty (60) days of the filing of the
answer.

        (b) Factual disputes subject to arbitration under this section include:
royalty payments due under Section 3.1 or Section 3.3, Thermal Cycler Supplier's
compliance with Sections 5.2 and

                                      -15-
<PAGE>

5.3, Thermal Cycler Supplier's compliance with the second sentence of Section
5.4, the occurrence of facts triggering expiration under Section 6.1 or
termination under Section 6.2 or Section 6.6, and Thermal Cycler Supplier's
right to notification and option under Article 11. Other factual disputes and
issues of law, including but not limited to the validity, enforceability, scope
or infringement of any patent, shall not be subject to arbitration under this
section.

        (c) The decision of the arbitration tribunal shall be final and judgment
thereon may be entered in any competent state or federal court in New York for
judicial acceptance of such award and order of enforcement. Each party hereby
submits itself to the jurisdiction of the state and federal courts in New York
for the entry of judgment with respect to decisions of arbitrators hereunder.

        12.5 Negotiation. Prior to commencing any lawsuit with respect to any
claim or controversy under this Agreement or the interpretation thereof, or
prior to demanding arbitration under Section 12.4, each party agrees to consult
with the other party to attempt to resolve the claim or controversy. The Parties
agree to attempt in good faith to achieve a resolution through consultation.

        12.6 Nothing in this Agreement shall be construed to require the
commission of any act contrary to law, and wherever there is any conflict
between any provision of this Agreement or concerning the legal right of the
Parties to enter into this contract and any statute, law or ordinance, the
latter shall prevail, but the provision shall be limited only to the extent
necessary.

        12.7 If any provision of this Agreement is held or discovered to both
parties' satisfaction to be illegal, invalid or unenforceable in any
jurisdiction or to render any patent in that jurisdiction unenforceable, the
provisions as it applies to that jurisdiction only shall be replaced
automatically, as part of the document, by a provision as similar in terms as
possible but not subject to such infirmity, in order to achieve the intent of
the parties to the extent possible. In any event, as to that jurisdiction all
other provisions of this Agreement shall be deemed valid and enforceable to the
full extent possible.

                                      -16-
<PAGE>

        IN WITNESS WHEREOF, the Parties hereto, have duly executed this
Agreement on the date(s) indicated below.

THE PERKIN-ELMER CORPORATION                 STRATAGENE

By:  /s/ MICHAEL W. HUNKAPILLER              By: /s/ JOSEPH SORGE
   --------------------------------             --------------------------------
     Michael W. Hunkapiller, Ph.D.

Title:    Vice President                     Title:    CEO
      -----------------------------                 ----------------------------

Date:     4/20/95                            Date:     4/19/95
     ------------------------------               ------------------------------

                                      -17-
<PAGE>
APPENDIX A

                             SUMMARY ROYALTY REPORT
                THERMAL CYCLER SUPPLIER AUTHORIZATION AGREEMENT
                      FOR THE PERIOD __/__/95 TO __/__/95

THERMAL CYCLER(TC) SUPPLIER: STRATAGENE     FOR SALES IN THE COUNTRY OF_________

LICENSE NUMBER: __________      EFFECTIVE DATE: __/__/__

     [ ] Check here if there were no sales for this period

<Table>
<Caption>
--------------------------------------------------------------------------------------------------------------------------
                                                                       ROYALTY (IN$) PER TC:
     TC MODEL NO.        NO. OF TCS     SAMPLE CAPACITY     *** + *** X (MAX. SAMPLE CAPACITY - ***)/*** *    ROYALTY DUE
--------------------------------------------------------------------------------------------------------------------------
<S>                      <C>            <C>                 <C>                                               <C>
1.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
2.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
3.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
4.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
5.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
6.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
                                                                                          TOTAL ROYALTY EARNED
                                                                                                                ----------
                                                                                          APPLICABLE CREDIT**
                                                                                                                ----------
                                                                                          ROYALTY PAYMENT DUE
                                                                                                                ----------
</Table>

* The fraction (max. sample capacity - ***)/*** is rounded to the next higher
whole number
** Please attach supporting or supplemental data to this sheet

I HEREBY CERTIFY THE INFORMATION SET FORTH ABOVE IS CORRECT AND COMPLETE WITH
RESPECT TO THE AMOUNTS DUE UNDER THE APPLICABLE LICENSE AGREEMENT.

By:                       Title:                        Date:
   ---------------------        -----------------------      -------------------
Name (please print):
                    ------------------------------
================================================================================
THE PERKIN-ELMER CORPORATION
SEND REPORT TO:
Director of Licensing, Applied Biosystems Division, The Perkin-Elmer Corp., 850
Lincoln Centre Dr., Foster City, CA 94404

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

TC Supplier Authorization Agreement    -18-                  Stratagene -4-14-95

<PAGE>
APPENDIX A - page 2

                             SUMMARY ROYALTY REPORT
                THERMAL CYCLER SUPPLIER AUTHORIZATION AGREEMENT
                      FOR THE PERIOD __/__/9_ TO __/__/9_

THERMAL CYCLER(TC) SUPPLIER: STRATAGENE     FOR SALES IN THE COUNTRY OF_________

LICENSE NUMBER: __________      EFFECTIVE DATE: __/__/__

     [ ] Check here if there were no sales for this period

<Table>
<Caption>
--------------------------------------------------------------------------------------------------------------------------
                                                                       ROYALTY (IN$) PER TC:
     TC MODEL NO.        NO. OF TCS     SAMPLE CAPACITY     *** + *** X (MAX. SAMPLE CAPACITY - ***)/*** *    ROYALTY DUE
--------------------------------------------------------------------------------------------------------------------------
<S>                      <C>            <C>                 <C>                                               <C>
1.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
2.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
3.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
4.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
5.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
6.
  ------------------     ---------      ---------------     ------------------------------------------          ----------
                                                                                          TOTAL ROYALTY EARNED
                                                                                                                ----------
                                                                                          APPLICABLE CREDIT**
                                                                                                                ----------
                                                                                          ROYALTY PAYMENT DUE
                                                                                                                ----------
</Table>

* The fraction (max. sample capacity - ***)/*** is rounded to the next higher
whole number
** Please attach supporting or supplemental data to this sheet

I HEREBY CERTIFY THE INFORMATION SET FORTH ABOVE IS CORRECT AND COMPLETE WITH
RESPECT TO THE AMOUNTS DUE UNDER THE APPLICABLE LICENSE AGREEMENT.

By:                       Title:                        Date:
   ---------------------        -----------------------      -------------------
Name (please print):
                    ------------------------------
================================================================================
THE PERKIN-ELMER CORPORATION
SEND REPORT TO:
Director of Licensing, Applied Biosystems Division, The Perkin-Elmer Corp., 850
Lincoln Centre Dr., Foster City, CA 94404

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

TC Supplier Authorization Agreement    -19-                  Stratagene -4-14-95

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]